Ticarcillin hypersusceptibility in pseudomonas aeruginosa in cystic fibrosis by Hettiarachchi, IT et al.
vv




Citation: Hettiarachchi IT, O’Sullivan T, Wootton M, Smith A, Duckers J, et al. (2017) Ticarcillin Hypersusceptibility in Pseudomonas Aeruginosa in Cystic Fibrosis. 
Arch Pulmonol Respir Care 3(1): 067-071. DOI: http://dx.doi.org/10.17352/aprc.000028
Clinical Group 
Abstract
Background: A subpopulation of Pseudomonas aeruginosa (PsA) exists in cystic fi brosis (CF) patients 
that is hypersusceptible to ticarcillin, a carboxypenicillin, in vitro (Tichs strain) defi ned as a minimum 
inhibitory concentration (MIC) ≤4μg/ml. 
Methods: In a retrospective cohort study, isolates of PsA from CF (23), non-cystic fi brosis 
bronchiectasis (NCFB) (17) and control (18) patients were analysed. MICs for each isolate were determined 
using agar dilution against six antibiotics and interpreted using EUCAST breakpoints. Prevalence of Tichs 
in each cohort was calculated. A point prevalence survey was conducted in CF to review the patients’ 
clinical progress following PsA isolation. 
Results: Prevalence of the Tichs strain in PsA was 48%, 76% and 0% in the CF, NCFB and control cohorts 
respectively. A statistically signifi cant difference in geometric mean MIC was seen between the Tichs and 
non-Tichs cohorts in CF for ticarcillin (as expected) and temocillin (p=0.041and p=0.036 respectively). A 
similar trend was observed in NCFB for ticarcillin (p=0.038) and temocillin (p=0.067), although statistical 
signifi cance was not reached for the latter. 
In CF, the Tichs strain demonstrated lower MICs to all antibiotics tested apart from gentamicin 
compared to their non-Tichs counterparts. Those who had the Tichs strain in CF had fewer antibiotics 
(13.9 days versus 23.5 days, Tichs and non-Tichs respectively) although this result was not statistically 
signifi cant p=0.202. 
Conclusion: Our data supports the existence of a Tichs strain of PsA in our CF and NCFB patient 
populations. This strain correlated with reduced MICs to temocillin in CF, to which PsA would normally be 
resistant, which may be of clinical relevance.
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Pseudomonas aeruginosa (PsA) is the commonest organism 
cultured from sputum of adult CF patients, with approximately 
80% of patients being infected by the age of 18 [1,2]. Antibiotic 
resistance in PsA is a growing problem with prevalence of 
multi-drug resistant pseudomonas aeruginosa (MDRPA) in 
CF reported as high as 35% amongst some adult CF centres 
[3]. One study found CF related diabetes, long-term inhaled 
tobramycin use and frequent acute pulmonary exacerbations 
requiring hospitalisation or intravenous antibiotics to be 
independent risk factors for MDRPA [4]. 
Ticarcillin-clavulanate, a caboxypenicillin is sometimes 
used in combination to treat PsA pulmonary exacerbations in 
CF. The existence of an intriguing subpopulation of PsA that is 
hypersusceptible to carbenicillin in vitro (defi ned as a minimum 
inhibitory concentration [MIC] ≤4μg/ml) in the sputum was 
fi rst described in the 1970s [5,6]. Interestingly, majority of 
these strains were isolated from CF patients who are often 
colonised and/or infected with multi-resistant strains of PsA. 
Early studies reported a prevalence of this hypersusceptible 
strain in the CF sputums to be as high as 27%-55% and found 
these strains to be distributed evenly among the mucoid and 
non-mucoid populations of PsA [5,6]. Several studies have 
since found that this hypersusceptible strain, dubbed Tichs 
contains mutations in MexAB-OprM (which exports -lactams, 
fl uoroquinolones, tetracyclines, macrolides, chloramphenicol 
and trimethoprim) and MexXY (exports aminoglycosides, 
tetracycline and erythromycin) effl ux pumps [7-9]. 
Temocillin is a semi-synthetic 6--methoxy derivative 
of ticarcillin and is used to treat exacerbations in CF patients, 
especially those colonised with Burkholderia cepacia [10,11]. 
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However, PsA is intrinsically resistant to temocillin with 
reported high MICs (128-256mg/L) [10-13]. This is thought to 
relate to poor permeation across the outer membrane, effl ux 
pumps and/or reduced binding to penicillin binding proteins 
[10]. Buyck et al., demonstrated the Tichs strain in CF to also 
be hypersusceptible to temocillin, with MICs ranging between 
1 and 4 [8]. The authors concluded that temocillin could 
contribute to the eradication of PsA in this Tichs population. A 
more recent publication found 29% of their 333 CF PsA isolates 
to have temocillin MICs ≤16 mg/L and 30-60% of these were 
resistant to conventional antipseudomonal antibiotics, making 
temocillin a very attractive therapeutic option [9]. 
Our aim was to determine the prevalence of the Tichs strain 
in chronic PsA isolates from our cohort of CF patients and to 
compare this to NCFB patients and controls. We also examined 
the impact of the Tichs strain on temocillin and other anti-
pseudomonal antibiotics. Finally, we attempted to assess the 
clinical implications of Tichs on CF patients. 
Methods
Study design, sample collection and laboratory proces-
sing 
A retrospective observational cohort study at the All Wales 
Adult Cystic Fibrosis Centre (AWACFC), University Hospital 
of Llandough, United Kingdom was performed between 2013 
and 2015. Isolates of PsA from clinical specimens are stored in 
frozen conditions at -80C at our laboratory. 23 isolates of PsA 
from sputum of CF patients and 17 PsA isolates from sputum 
of NCFB were retrieved from the freezer and compared to 18 
isolates of PsA recovered from blood cultures, tissues, bone 
and joint fl uid from control patients without pre-existing lung 
disease. Control PsA samples were obtained from sites other 
than sputum because isolation of PsA from sputum usually 
indicates underlying chronic lung disease and therefore it is 
impossible to collect sputum growing PsA from patients who 
have structurally normal lungs. Laboratory processing of 
samples was conducted in accordance with the local standard 
operating procedures which are derived from the UK Standards 
for Microbiology Investigations guidance [14]. 
Agar dilution was performed on Mueller Hinton agar using 
log2 dilutions of all antimicrobials in the range 0.008mg/L 
to 128mg/L using a standardised method [15]. MICs were 
interpreted using EUCAST breakpoints (version 7.1) [12]. E.coli 
NCTC 10418, E.coli ATCC 25922 and P.aeruginosa ATCC 27853 
were used as control strains in all the experiments conducted. 
Sputum from CF patients and NCFB patients were collected 
from adult patients attending dedicated outpatient clinics at 
the University Hospital of Llandough. Respiratory samples were 
processed according to the laboratory standardised operating 
procedure and samples growing PsA are usually stored in the 
freezer. These PsA isolates and the PsA isolates from controls 
were tracked through an electronic database and were retrieved 
from the freezer. For each cohort the prevalence of the Tichs 
strain of PsA was calculated and the geometric mean MICs 
were compared between the different groups. 
For the CF cohort, we attempted to assess the clinical 
implications of the Tichs strain. We conducted a point prevalence 
survey to review antimicrobial prescription and clinical 
parameters at the time of PsA isolation. We followed up the CF 
cohort over a one year period to assess the number of antibiotic 
days, number of hospital admissions and FEV1 at annual review 
and best FEV1. 
Statistical analysis
Statistical analysis was performed using R (version 
3.2.2) using descriptive, ANOVA, Mann Whitney U Test, and 
regression analyses. 
The CF and NCFB cohorts had two sub groups (Tichs and 
Non-Tichs strains) and sample sizes were unequal. A one way 
ANOVA (confi dence intervals at 2.5% and 97.5%) test and the 
dependent 2-group Wilcoxon rank sum test with continuity 
correction were used. Multiple regression was used to 
investigate whether there was a signifi cant difference between 
antibiotics upon comparison of the three groups. 
In the CF cohort the subgroups Tichs and non-Tichs PsA 
cohorts were directly compared. We used a Welch Two Sample 




Cystic Fibrosis patients: Twenty-three CF patients with 
chronic PsA colonisation were assessed in this study (Table 1). 
The mean age was 31.3 years ± 8.8 years (age range-19 to 54). 
70% of this cohort was female. The patients in the CF cohort 
had more female patients compared to the NCFB and control 
cohorts. CF patients were younger than patients in the two 
other cohorts as would be expected. The average duration of 
colonisation with PsA was 14 years. Patients were frequently 
colonised with multiple organisms. During the study period 
two patients had lung transplants and two patients died of CF 
related complications. 
Non-Cystic Fibrosis Bronchiectasis patients: Seventeen 
PsA samples from twelve NCFB patients were assessed. For 
two patients several different strains of PsA were included in 
the analysis. The mean age was 63.6±10.9 years (age range- 41 
to 76). 42% of this cohort was female. The average duration 
of colonisation with PsA in our NCFB cohort was 6 years. 
Within the NCFB cohort, only two patients were treated with 
antibiotics for an infective exacerbation at the time PsA was 
isolated in their sputum for this study. The mean duration of 
antibiotics was 14 days. The mean FEV1 in this cohort was 1.24L 
and the mean percentage predicted FEV1 was 57%. 
Control patients
In our control group of 18 patients, the mean age was 
68.6±21.9 years (age range- 5 to 91). 50% of the cohort was 
female. 
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Prevalence of the Tichs strain and antibiotic suscepti-
bilities 
The prevalence of the Tichs strain in PsA in our cohort of 
CF patients was 48% compared to a prevalence of 76% in the 
NCFB cohort and 0% in controls. Resistant strains of PsA were 
more prevalent in the CF patients compared to NCFB patients 
and controls, except for temocillin and ticarcillin (Table 2). 
Interestingly, the MIC50 for ticarcillin in the CF cohort was 
4 fold lower than the MIC50 for ticarcillin in the controls. 
For temocillin, the MIC50 was 16 fold lower in the CF cohort 
compared to the controls. 
We calculated the geometric mean MICs for each antibiotic 
for each cohort (CF and NCFB, Tichs and non-Tichs) (Table 3). In 
the CF cohort, the Tichs strain was associated with reduced MICs 
to most antibiotics compared to their non-Tichs counterparts 
(apart from gentamicin) in a phenomenon described previously 
[4]. A statistically signifi cant difference in geometric mean 
MIC between the Tichs and non-Tichs cohorts in CF was seen 
for ticarcillin, as to be expected, and temocillin (p=0.041and 
p=0.036 respectively). 
In the NCFB cohort a similar trend of reduced MICs with 
the Tichs strain was observed compared to the non-Tichs strain 
for all antibiotics apart from ciprofl oxacin, with a statistically 
signifi cant difference in geometric mean MIC seen again for 
ticarcillin (p=0.039). A marked reduction in geometric mean 
MIC was seen between the two groups for temocillin (geometric 
mean MIC 1.79 in Tichs versus 64 in non-Tichs) but these 
fi ndings were just under the threshold of reaching statistical 
signifi cance (p=0.06). 
Cystic fi brosis- clinical outcomes 
We conducted a point prevalence survey for patients within 
the CF cohort, to evaluate the clinical outcomes at the time 
PsA was isolated in the sputum. Of the 23 CF patients, all were 
colonised chronically with PsA, 14 (61%) were treated with 
antibiotics for an infective exacerbation of their CF. Patients 
received a combination of two or three antibiotics to treat the 
CF exacerbation. The mean duration of antibiotics to treat 
this episode was 15.1±5.4 days (range 8 to 24 days).Of those 
admitted the mean length of stay in hospital was 13 days; the 
mean FEV1 on admission was 1.3L and on discharge was 1.7L. 
We reviewed the clinical progress and outcomes of the CF 
patients during the 1 year period following PsA isolation for 
this particular episode (Table 4). We excluded patients who 
died or had a transplant from this analysis. A mean of 18 days 
of total (hospital and home) IV antibiotics were required over 
a one year period. A key fi nding in this study was that those 
who had the Tichs strain of PsA in CF had fewer antibiotics 
(total antibiotics-13.9 days versus 23.5 days, Tichs and non-
Tichs respectively) although this result was not statistically 
signifi cant p=0.2883. 
Discussion 
This study demonstrates that a signifi cant proportion 
of our adult patients with CF tested over a 2 year period are 
colonised and/ or infected with the ticarcillin hypersusceptible 
strain of PsA. 48% of our CF patients tested carried this strain. 


























BMI (mean ± SD) kg/m2 21.9 ±3.4 28±3.8 Not available
Additional organisms cultured, n (%)
• Staphylococcus aureus 21 (91%) 2 (12%)
 Not applicable 
• Burkholderia cepacia 1 (4%) -
• Serratia marcescens 4 (17%) -
• Stenotrophomonas maltophilia 7 (30%) 1 (6%)
• Acinetobacter baumanii 2 (9%) -
• Enterobacter sp. 2 (9%) 1 (6%)
• Escherichia coli 1 (4%) 1 (6%)
• Proteus mirabilis - 1 (6%)
• Klebsiella pneumoniae - 2 (12%)
• Morganella morganii - 1 (6%)
• Achromobacter xylosoxidans 1 (4%) -
• Aspergillus sp. 9 (39%) 2 (12%)
• Penicillium sp. 3 (4%) 1 (6%)
• Exophiala sp. 1 (4%) 1 (6%)
• Mycobacterium sp. 5 (22%) 1 (6%)
Table 2: MIC range, MIC 50, MIC 90 and % resistant and % sensitive PsA isolates for CF patients, NCFB patients and controls (C).
Meropenem Ceftazidime Ticarcillin Temocillin Ciprofl oxacin Gentamicin
























0.03-4 1-64 0.032-4 0.25-4
MIC 50 0.5 0.125 0.125 4 1.5 4 8 1 32 8 4 128 1 0.25 0.06 2 0.25 1
MIC 90 4 4 1 128 8 16 128 128 128 128 128 128 4 32 0.5 64 2 2
%R 21% 6% 6% 28% 12% 16% 36% 18% 74% NA NA NA 63% 47% 7% 32% 0% 0%
%S 79% 82% 94% 72% 88% 84% 64% 82% 26% NA NA NA 37% 53% 93% 68% 100% 100% 
EUCAST BP S≤2, >8 R S≤8> R S≤16> R NA S≤0.5 ≥ R S≤4> R
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Rates of the Tichs strain in CF PsA previously reported have 
been variable (28% [5,9] to 55%[6]). This Tichs strain was 
also found in high prevalence in our NCFB cohort (76%). We 
are the second study to look at the prevalence of Tichs in this 
cohort since the original study where a prevalence of 62% was 
reported in NCFB5. 
The Tichs strain is of great interest to both microbiologists 
and CF physicians due to the in vitro hypersusceptibility it 
can demonstrate to several antimicrobials which can be of 
signifi cant clinical benefi t. A recent study by Chalhoub et al. 
called for the introduction of routine susceptibility testing of 
temocillin for PsA from CF patients [9]. Several studies have 
attributed the Tichs phenotype to the inactivation of the MexAB-
OprM effl ux pump in PsA, which usually confers signifi cant 
resistance to antibiotics when overproduced [6-9]. However, it 
is not possible to defi nitively comment on precise mechanisms 
of resistance in our isolates as we did not determine these in 
our study. 
A discernible fi nding in our study was the statistically 
signifi cant difference in geometric mean MICs seen for 
ticarcillin and temocillin in the CF Tichs cohort compared to the 
CF non- Tichs cohort (p=0.041 and p=0.036 respectively). These 
fi ndings were seen again in the NCFB Tichs cohort, although 
statistical signifi cance was not met for temocillin (p=0.067). 
Traditionally temocillin has no activity against PsA due to its 
poor permeation across PsA outer membrane, effl ux pumps 
and/or reduced binding to penicillin binding proteins [10]. 
However, this fi nding of a drop in temocillin MICs in Tichs 
has led to the hypothesis that temocillin may be used in the 
eradication of PsA in this particular cohort [8,9]. The Tichs 
strains of PsA were also hypersusceptible to other  lactam 
antibiotics compared to their non-Tichs counterparts (table 3). 
Although these results were not statistically signifi cant there 
maybe clinical utility to this fi nding. 
The clinical implications of the Tichs phenotype have 
never been studied. We conducted a point prevalence survey 
in an attempt to assess the impact of Tichs in CF. A notable 
observation in this study was that CF patients with the Tichs 
strain required fewer days of total antibiotics over a one year 
period than those without this strain. However these fi ndings 
did not meet statistical signifi cance and further work would be 
required with to assess this further. 
Despite the laboratory observations, it is important to 
note that in vitro susceptibilities of Tichs strains often do 
not represent the ‘real life’ susceptibility of the organism, 
particularly within the CF lung where organisms live within 
complex biofi lms. In addition, the existence of multiple strains 
of PsA in the chronic CF lung is well recognised and assessing 
the inter-bacterial relationships as to whether or not there is a 
dominant organism is extremely challenging. The differences 
in PsA lung biofi lms and biofi lms within other sites such as 
prosthetic joints has not been studied. It would be of interest 
to investigate whether the latter patient group, particularly 
patients with recurrent prosthetic joint infections with PsA, 
possess the Tichs strain and the clinical implications of this. 
It is postulated that the Tichs strain may provide a survival 
advantage to PsA, particularly within the hostile environments 
within CF airways. This may explain the higher prevalence of 
the Tichs strain in the CF and NCFB cohorts compared to controls 
where the Tichs strain was absent. Another hypothesis for the 
prevalence of this strain could be the use of broad spectrum, 
intravenous antibiotics in the CF/NCFB cohorts, thus selecting 
out the Tichs strain in this population compared to controls. 
The main limitation of this study is the small sample size in 
each group which may affect the precision of our results. The 
PsA isolates used were obtained from frozen conditions which 
may impact on the phenotypic characteristics and resistance 
patterns observed. Five isolates from the CF cohort and one 
isolate from the NCFB cohort did not grow on the medium of 
choice and required MIC determination by gradient strip which 
may affect the validity of our results. We did not study the 
underlying mechanisms of resistance contributing to the Tichs 
phenotype which would be interesting to observe. 
Further studies are needed with larger sample sizes 
and longer follow up periods to observe clinical outcomes, 
particularly those patients with the Tichs strain who received 
Table 3: Geometric mean MICs of Tichs strain and non-tichs strain: CF versus NCFB.
CF NCFB
Geometric mean MIC (Tichs 
strain) n=11
Geometric mean MIC (Non-Tichs 
strain) n=12
P value 
Geometric mean MIC (Tichs 
strain) n=13
Geometric mean MIC (Non-Tichs 
strain) n=4
P value 
Meropenem 0.67 2.93 0.989 0.12 1.19 0.4075 
Ceftazidime 5.04 28.45 0.143 1.24 19.03 0.6216
Ticarcillin 1.39 62.0 0.041 0.69 76.11 0.0387
Temocillin 4.15 61.67 0.036 1.79 64.00 0.0677
Ciprofl oxacin 1.34 3.33 0.593 0.92 0.30 0.1363
Gentamicin 13.6 5.70 0.444 0.28 0.50






P value and confi dence 
interval
Total number of IV 
antibiotic days over 1 year 
13.9 23.5 0.2883 (95% CI -35.5 to 7.4)
Hospital IV days 9.67 12 0.5781 (95% CI -19.0 to 23.5) 
Home IV days 12.2 35 0.2359 (95% CI -138.9 to 28.9)
Number of admissions/
year
1.8 1.9 0.7893 (95% CI -8.9 to 3.9)
FEV1 at annual review 2.29 2.09 0.5469 (95% CI -1.1 to 2.0)
Best FEV1 2.49 2.36 0.9453 (95% CI -0.9 to 2.1) 
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temocillin. Another interesting avenue to explore would be 
to investigate whether the Tichs strain exists in other settings 
of chronic pseudomonal infections such as bone and joint 
infections and examine the clinical implications of this. 
Conclusion
In conclusion, our data supports the existence of the Tichs 
strain of PsA in CF and NCFB patients and had the highest 
prevalence in our NCFB cohort. In CF, this strain demonstrated 
statistically signifi cant reduction in MICs in vitro to temocillin, 
to which PsA is conventionally resistant to. This is an important 
fi nding in an era of increasing multi-drug resistance and the 
scarcity in production of new antimicrobials, where temocillin, 
often used to treat Burkholderia cepacia in CF may provide an 
attractive option in also treating PsA. Our study adds to the 
evidence to support routine susceptibility testing of temocillin 
for all PsA isolates from CF and NCFB patients. Further studies 
are required to follow up the longer term outcomes of patients 
with the Tichs strain. 
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